Physician profile
Robert Friedman
NPI 1568465748
$2,738.55
in general payments reported to CMS, 2019-2025
22 companies · $503 in 2025
The $503 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $276 · 2021: $471 · 2022: $205 · 2023: $318 · 2024: $332 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $437.41 | 2019-2025 | Clareon, Clareon Panoptix Pro, Eysuvis |
| Kala Pharmaceuticals, INC. | $323.36 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $274.13 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $267.82 | 2024-2025 | Xdemvy |
| Rxsight INC | $244.32 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $242.55 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $187.95 | 2019-2023 | Cequa |
| Oyster Point Pharma, INC. | $154.87 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $110.47 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $98.79 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $63.30 | 2021-2023 | Acthar |
| Harrow Eye, LLC | $47.67 | 2024 | Vevye |
| Dompe US, INC. | $45.87 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $41.16 | 2019-2021 | |
| Abbvie INC. | $40.43 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $36.33 | 2024 | Izervay |
| Omeros Corporation | $36.26 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $22.97 | 2020 | |
| Shire North American Group INC | $18.89 | 2019 | |
| Glaukos Corporation | $15.62 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Thea Pharma INC. | $14.96 | 2024 | Iyuzeh |
| Biotissue Holdings INC. | $13.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.